Gilbert Technologies is a Dutch company that designs and develops medical devices to improve health care, patient care and that offers a better quality of life through innovative and disruptive sustainable health technologies. The technology is applied in novel medical inhalation devices with market-leading lung deposition characteristics for pulmonary medicine administration for Cystic Fibrosis (CF), Asthma, Oncology (Lung cancer), Pulmonary Arterial Hypertension, as well as Non-CF Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis, Transplantation, Pain management, Vaccination and other indications.
An innovative monodisperse aerosol technology where droplet size can vary in such a way that medication can be accurately and locally targeted in the lungs.
We turn complexity into simplicity. We expand access to healthcare and offer better convenience, comfort and mobility to patients and enhance patient adherence.
Through our core business, we stimulate socially responsible initiatives in health care by utilizing innovative development opportunities.
Our strategy is to use science-based innovation to deliver better patient outcomes. We aim to lead in certain growing areas of healthcare.
“Gilbert Technologies’ EHDA technology has the potential to offer unique benefits to patients for aerosolization and medication targeting of more complex and advanced molecular entities for respiratory diseases and for pulmonary administration of molecules for other indication areas.”
“Gilbert Technologies’ EHDA technology is one of the most promising innovations in device inhalation technology, offering substantial advantages to patients compared to current commercial available inhalation technology solutions.”
• TU Delft
• NHL University of Applied Sciences
• University Medical Center Utrecht
Gilbert Technologies B.V.
High Tech Campus 27, P148
5656 AE Eindhoven – NL
Gilbert Technologies 2020